Ikena Oncology to Participate in September 2021 Virtual Investor Conferences

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced that management will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference taking place on September 9-15, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference, taking place on September 13-15, 2021.

Details are as follows:

Conference: Morgan Stanley 19

th

Annual Global Healthcare Conference
Fireside Chat: Friday, September 10, 2021, 10:15am EST; live and available for replay        
Webcast Link

Conference: H.C. Wainwright 23

rd

Annual Global Investment Conference

Date: Monday, September 13, 2021; available for replay        
Webcast Link

The presentation webcasts can be accessed by visiting the Investors & Media section of the company’s website at www.ikenaoncology.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.

About Ikena Oncology

Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing multiple programs that target tumor markers as well as programs targeting the tumor microenvironment. The Company’s lead program, IK-930, is a TEAD inhibitor targeting the Hippo signaling pathway, a pathway that can drive formation and increase survival of tumors and also drives development of resistance to multiple existing therapies. Additional programs include an ERK5 inhibitor program targeting the KRAS signaling pathway and several programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb. Ikena’s pipeline is built on targeting genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

Media Contact:

Gwen Schanker
LifeSci Communications
[email protected]

Investor Contact:
Rebecca Cohen
Ikena Oncology
[email protected]

 



Opthea To Present at September Investor Conferences

MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the following investor conferences in September:

Citi’s 16

th

Annual BioPharma Virtual Conference
Date: Thursday, September 9, 2021 8:50 am ET (11:50 pm AEST)
Panel: Eyes on the Prize – Next Generation Retinal Therapeutics

H.C. Wainwright Annual Healthcare Conference
Date: Monday, September 13, 2021 7:00 am ET (9:00 pm AEST)

Oppenheimer Healthcare Fall Summit
Date: Monday, September 20, 2021 4:35 pm ET (Tuesday, September 21, 2021, 7:35 am AEST)
The presentations may be accessed on the Investors page of the Opthea website at https://www.opthea.com/presentations/.

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

Company & Media Enquiries:

U.S.A. & International: Australia:
Sam Martin Rudi Michelson
Argot Partners Monsoon Communications
Tel: +1 212-600-1902 Tel: +61 (0) 3 9620 3333
[email protected]  

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399 Email: [email protected] Web: www.opthea.com 



Methode Electronics, Inc. Reports Fiscal 2022 First Quarter Financial Results

  • Net Sales Up 51%
  • Electric and Hybrid Vehicle Application Sales Growth
  • Income from Operations Up 147%
  • Continued Share Buyback

CHICAGO, Sept. 02, 2021 (GLOBE NEWSWIRE) — Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, LED lighting and power distribution applications, today announced financial results for the first quarter of Fiscal 2022 ended July 31, 2021.

Fiscal First Quarter 2022 Highlights

  • Net sales were $287.8 million
  • Electric and hybrid vehicle applications were 16 percent of net sales
  • Income from operations was $34.1 million
  • Net income was $29.1 million, or $0.76 per diluted share
  • Company purchased 157,513 shares of its common stock for $7.6 million
  • Company increased quarterly dividend from $0.11 per share to $0.14 per share

Consolidated Fiscal First Quarter 2022 Financial Results

Methode’s net sales were $287.8 million, which included a favorable foreign currency impact of $10.3 million, up 50.8% compared to $190.9 million in the same quarter of fiscal 2021. Excluding the foreign currency impact, net sales were up 45.4% compared to the same quarter of fiscal 2021. The increase was mainly due to lower sales in the prior year quarter from the impact of the COVID-19 pandemic but was also driven by higher sales of electric and hybrid vehicle products.

Income from operations was $34.1 million or 11.8% of net sales, compared to $13.8 million or 7.2% of net sales in the same quarter of fiscal 2021. The $20.3 million increase was primarily due to the higher sales volume and was partially offset by higher material, logistics, and labor costs resulting from supply chain shortages and disruptions and by higher stock-based compensation expense. The increase was also driven by the lack of restructuring costs in the quarter, compared to $3.4 million in the same quarter of fiscal 2021.

Other income was $1.8 million, compared to $3.4 million in the same quarter of fiscal 2021. The decrease was primarily due to lower international government assistance and unfavorable foreign exchange.

Income tax expense was $5.7 million, compared to a tax benefit of $5.1 million in the same quarter of fiscal 2021. The increase was primarily due to $7.8 million in discrete tax benefits recorded in the prior year first quarter. The effective tax rate was 16.4%, compared to 17.2% in the same quarter of fiscal 2021 when the discrete tax benefits were excluded.

Net income was $29.1 million or $0.76 per diluted share, compared to $20.7 million or $0.54 per diluted share in the same quarter of fiscal 2021.

EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization of Intangibles), a non-GAAP financial measure, was $48.5 million, compared to $29.3 million in the same quarter of fiscal 2021.

Debt was $235.4 million at the end of the quarter, compared to $240.1 million at the end of fiscal 2021. Net debt, a non-GAAP financial measure defined as debt less cash and cash equivalents, was $27.5 million, compared to $6.9 million at the end of fiscal 2021.

Free cash flow, a non-GAAP financial measure defined as net cash provided by operating activities less purchases of property, plant, and equipment, was a negative $6.2 million, compared to a positive $4.8 million in the same quarter of fiscal 2021. The decrease was mainly due to investment in inventory to support the increased sales and higher capital expenditures.

On March 31, 2021, the Board of Directors authorized the purchase of up to $100.0 million of Methode common stock. The company purchased and retired 157,513 shares of common stock for $7.6 million in the quarter. As of July 31, 2021, a total of 325,462 shares have been purchased under the authorization at a total cost of $15.1 million.

Segment Fiscal First Quarter 2022 Financial Results

Comparing the Automotive segment’s quarter to the same quarter of fiscal 2021,

  • Net sales were $195.8 million, up $70.7 million or 56.5% from $125.1 million. The increase was mainly due to lower sales in the prior year quarter from the impact of the pandemic. Sales were higher in Europe, North America and Asia driven in part by higher sales of electric and hybrid vehicle products. The segment net sales in the quarter were positively impacted by $7.1 million from foreign currency translation.
  • Income from operations was $27.3 million, up $12.0 million or 78.4% from $15.3 million primarily due to higher sales volume. The increase was partially offset by higher logistics and labor costs. Income from operations was 13.9% of net sales, up from 12.2%.

Comparing the Industrial segment’s quarter to the same quarter of fiscal 2021,

  • Net sales were $78.5 million, up $26.5 million or 51.0% from $52.0 million. The increase was mainly due to lower sales in the prior year quarter from the impact of the pandemic. All product categories had higher sales led by commercial vehicle lighting and EV busbars. The segment net sales in the quarter were also positively impacted by $3.2 million from foreign currency translation.
  • Income from operations was $20.2 million, up $13.2 million or 188.6% from $7.0 million primarily due to higher sales volume. The increase was partially offset by higher material and logistics costs. Income from operations was 25.7% of net sales, up from 13.5%.

Comparing the Interface segment’s quarter to the same quarter of fiscal 2021,

  • Net sales were $12.7 million, down $0.7 million or 5.2% from $13.4 million primarily due to lower sales volume due to semiconductor shortages.
  • Income from operations was $1.1 million, unchanged from $1.1 million in the prior year. Income from operations was 8.7% of net sales, up from 8.2%.

Comparing the Medical segment’s quarter to the same quarter of fiscal 2021,

  • Net sales were $0.8 million, up from $0.4 million. While sales increased 100%, the pandemic continues to negatively impact hospital evaluation opportunities.
  • Loss from operations was $1.2 million, compared to a loss of $1.6 million.

Fiscal 2022 Full Year Guidance

For the fiscal year 2022, the company reaffirmed its expectation for net sales to be in the range of $1,175 to $1,235 million and for diluted earnings per share to be in the range of $3.35 to $3.75.

The guidance is subject to disruption due to a variety of factors including the ongoing semiconductor shortage and other supply chain disruptions.

Management Comments

President and Chief Executive Officer Donald W. Duda said, “Our businesses continued to be impacted by the ongoing supply chain challenges in the quarter. As a result of our teams’ relentless efforts to mitigate those headwinds, Methode was able to achieve sales within our guidance and once again increase EV product sales. We also continued to return capital to shareholders via our stock buyback program and previously announced quarterly dividend increase.”

Mr. Duda added, “We have reaffirmed our guidance for the full year. However, the ongoing supply chain challenges could potentially result in performance below the midpoint of the ranges, as the situation is very dynamic and will likely remain challenging.”  

Non-GAAP Financial Measures

To supplement the company’s financial statements presented in accordance with generally accepted accounting principles in the United States (“GAAP”), Methode uses certain non-GAAP financial measures, such as EBITDA, Net Debt, and Free Cash Flow. Reconciliation to the nearest GAAP measures of all non-GAAP measures included in this press release can be found at the end of this release. Management believes EBITDA is useful to investors as it is a measure that is commonly used by other companies in our industry and provides a comparison for investors to the company’s performance versus its competitors. Management believes Net Debt is a meaningful measure to investors because management assesses the company’s leverage position after considering available cash that could be used to repay outstanding debt. Management believes Free Cash Flow is a meaningful measure to investors because management reviews cash flows generated from operations after taking into consideration capital expenditures, which are both necessary to maintain the company’s asset base and which are expected to generate future cash flows from operations. Methode’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP.

Conference Call

The company will conduct a conference call and webcast to review financial and operational highlights led by its President and Chief Executive Officer, Donald W. Duda, and Chief Financial Officer, Ronald L. G. Tsoumas, today at 10:00 a.m. CDT.

To participate in the conference call, please dial 844-602-0380 (domestic) or 862-298-0970 (international) at least five minutes prior to the start of the event. A simultaneous webcast can be accessed through the company’s website, www.methode.com, on the Investors page.

A replay of the teleconference will be available shortly after the call through September 16, 2021, by dialing 877-481-4010 and providing passcode 42445. A webcast replay will also be available through the company’s website, www.methode.com, on the Investors page.

About Methode Electronics, Inc.

Methode Electronics, Inc. (NYSE: MEI) is a leading global supplier of custom-engineered solutions with sales, engineering and manufacturing locations in North America, Europe, Middle East and Asia. We design, engineer, and produce mechatronic products for OEMs utilizing our broad range of technologies for user interface, LED lighting system, power distribution and sensor applications.

Our solutions are found in the end markets of transportation (including automotive, commercial vehicle, e-bike, aerospace, bus, and rail), cloud computing infrastructure, construction equipment, consumer appliance, and medical devices. Our business is managed on a segment basis, with those segments being Automotive, Industrial, Interface and Medical.

Forward-Looking Statements

This press release contains certain forward-looking statements, which reflect management’s expectations regarding future events and operating performance and speak only as of the date hereof. These forward-looking statements are subject to the safe harbor protection provided under the securities laws. Methode undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in Methode’s expectations on a quarterly basis or otherwise. The forward-looking statements in this press release involve a number of risks and uncertainties. The factors that could cause actual results to differ materially from our expectations are detailed in Methode’s filings with the Securities and Exchange Commission, such as our annual and quarterly reports. Such factors may include, without limitation, the following: 1) Impact from pandemics, such as the COVID-19 pandemic; 2) Dependence on the automotive and commercial vehicle industries; 3) Dependence on our supply chain, including semiconductor suppliers; 4) Dependence on a small number of large customers, including two large automotive customers; 5) Dependence on the availability and price of materials; 6) Failure to attract and retain qualified personnel; 7) Timing, quality and cost of new program launches; 8) Risks related to conducting global operations; 9) Ability to compete effectively; 10) Investment in programs prior to the recognition of revenue; 11) Ability to withstand pricing pressures, including price reductions; 12) Impact from production delays or cancelled orders; 13) Ability to successfully benefit from acquisitions and divestitures; 14) Ability to withstand business interruptions; 15) Breaches to our information technology systems; 16) Ability to keep pace with rapid technological changes; 17) Ability to protect our intellectual property; 18) Costs associated with environmental, health and safety regulations; 19) International trade disputes resulting in tariffs and our ability to mitigate tariffs; 20) Impact from climate change and related regulations; 21) Ability to avoid design or manufacturing defects; 22) Recognition of goodwill and long-lived asset impairment charges; 23) Ability to manage our debt levels and any restrictions thereunder; 24) Currency fluctuations; 25) Income tax rate fluctuations; 26) Judgments related to accounting for tax positions; 27) Adjustments to compensation expense for performance-based awards; 28) Timing and magnitude of costs associated with restructuring activities; and 29) Impact to interest expense from the replacement or modification of LIBOR.

For Methode Electronics, Inc.

Robert K. Cherry
Vice President, Investor Relations
[email protected]
708-457-4030

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

(in millions, except share and per-share data)

  Three Months Ended  
  July 31, 2021     August 1, 2020  
Net sales $ 287.8     $ 190.9  
               
Cost of products sold   216.1       145.8  
               
Gross profit   71.7       45.1  
               
Selling and administrative expenses   32.8       26.6  
Amortization of intangibles   4.8       4.7  
               
Income from operations   34.1       13.8  
               
Interest expense, net   1.1       1.6  
Other income, net   (1.8 )     (3.4 )
               
Income before income taxes   34.8       15.6  
               
Income tax expense (benefit)   5.7       (5.1 )
               
Net income $ 29.1     $ 20.7  
               
Basic and diluted income per share:              
Basic $ 0.77     $ 0.55  
Diluted $ 0.76     $ 0.54  
               
Cash dividends per share $ 0.14     $ 0.11  
               
Weighted average number of shares outstanding:              
Basic   37,939,488       37,836,543  
Diluted   38,457,958       38,158,418  
               

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except share and per-share data)

    July 31, 2021     May 1, 2021  
    (unaudited)          
ASSETS                
Current assets:                
Cash and cash equivalents   $ 207.9     $ 233.2  
Accounts receivable, net     276.7       282.5  
Inventories     142.4       124.2  
Income taxes receivable     13.3       11.5  
Prepaid expenses and other current assets     20.6       22.6  
Total current assets     660.9       674.0  
Long-term assets:                
Property, plant and equipment, net     214.6       204.0  
Goodwill     235.2       235.6  
Other intangible assets, net     224.1       229.4  
Operating lease right-of-use assets, net     20.6       22.3  
Deferred tax assets     40.2       41.2  
Pre-production costs     27.8       25.0  
Other long-term assets     35.6       35.5  
Total long-term assets     798.1       793.0  
Total assets   $ 1,459.0     $ 1,467.0  
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current liabilities:                
Accounts payable   $ 110.8     $ 122.9  
Accrued employee liabilities     24.1       33.5  
Other accrued liabilities     28.7       25.0  
Short-term operating lease liabilities     5.9       6.1  
Short-term debt     14.8       14.9  
Income tax payable     19.8       20.3  
Total current liabilities     204.1       222.7  
Long-term liabilities:                
Long-term debt     220.6       225.2  
Long-term operating lease liabilities     16.1       17.5  
Long-term income taxes payable     24.8       24.8  
Other long-term liabilities     21.4       20.5  
Deferred tax liabilities     37.7       38.3  
Total long-term liabilities     320.6       326.3  
Total liabilities     524.7       549.0  
Shareholders’ equity:                
Common stock, $0.50 par value, 100,000,000 shares authorized, 39,544,645 shares and 39,644,913 shares issued as of July 31, 2021 and May 1, 2021, respectively     19.8       19.8  
Additional paid-in capital     161.2       157.6  
Accumulated other comprehensive income     2.9       6.1  
Treasury stock, 1,346,624 shares as of July 31, 2021 and May 1, 2021     (11.5 )     (11.5 )
Retained earnings     761.9       746.0  
Total shareholders’ equity     934.3       918.0  
Total liabilities and shareholders’ equity   $ 1,459.0     $ 1,467.0  
                 

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

    Three Months Ended  
    July 31, 2021     August 1, 2020  
Operating activities:                
Net income   $ 29.1     $ 20.7  
Adjustments to reconcile net income to net cash provided by operating activities:                
Depreciation and amortization     12.6       12.1  
Stock-based compensation expense     4.0       0.9  
Change in cash surrender value of life insurance     (0.4 )     (0.6 )
Amortization of debt issuance costs     0.2       0.2  
Gain on sale of property, plant and equipment     (0.4 )      
Change in deferred income taxes     (0.1 )     (6.2 )
Other     0.1       1.0  
Changes in operating assets and liabilities:                
Accounts receivable     4.7       (37.3 )
Inventories     (18.5 )     9.1  
Prepaid expenses and other assets     (5.0 )     1.5  
Accounts payable     (8.1 )     12.0  
Other liabilities     (8.5 )     3.0  
Net cash provided by operating activities     9.7       16.4  
                 
Investing activities:                
Purchases of property, plant and equipment     (15.9 )     (11.6 )
Sale of property, plant and equipment     0.5        
Net cash used in investing activities     (15.4 )     (11.6 )
                 
Financing activities:                
Taxes paid related to net share settlement of equity awards     (0.3 )     (3.9 )
Repayments of finance leases     (0.2 )     (0.1 )
Proceeds from exercise of stock options     0.5       0.1  
Purchases of common stock     (8.4 )      
Cash dividends     (5.2 )     (5.0 )
Repayments of borrowings     (4.7 )     (4.1 )
Net cash used in financing activities     (18.3 )     (13.0 )
Effect of foreign currency exchange rate changes on cash and cash equivalents     (1.3 )     1.9  
Decrease in cash and cash equivalents     (25.3 )     (6.3 )
Cash and cash equivalents at beginning of the period     233.2       217.3  
Cash and cash equivalents at end of the period   $ 207.9     $ 211.0  
                 
Supplemental cash flow information:                
Cash paid during the period for:                
Interest   $ 0.9     $ 1.5  
Income taxes, net of refunds   $ 7.3     $ 4.8  
Operating lease obligations   $ 1.9     $ 2.1  
                 

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP MEASURES (Unaudited)

(in millions)

    Three Months Ended  
    July 31, 2021     August 1, 2020  
EBITDA:                
Net income   $ 29.1     $ 20.7  
Income tax expense     5.7       (5.1 )
Interest expense, net     1.1       1.6  
Amortization of intangibles     4.8       4.7  
Depreciation     7.8       7.4  
EBITDA   $ 48.5     $ 29.3  

    Three Months Ended  
    July 31, 2021     August 1, 2020  
Free Cash Flow:                
Net cash provided by operating activities   $ 9.7     $ 16.4  
Purchases of property, plant and equipment     (15.9 )     (11.6 )
Free cash flow   $ (6.2 )   $ 4.8  

    July 31, 2021     May 1, 2021  
Net Debt:                
Short-term debt   $ 14.8     $ 14.9  
Long-term debt     220.6       225.2  
Total debt     235.4       240.1  
Less: cash and cash equivalents     (207.9 )     (233.2 )
Net debt   $ 27.5     $ 6.9  
                 



Instil Bio to Present at Upcoming Investor Conferences in September

DALLAS, Sept. 02, 2021 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in September:

Morgan Stanley 19

th

Annual Global Healthcare Conference

Fireside Chat: Thursday, September 9 at 2:00 p.m. ET

Baird’s 2021 Virtual Global Healthcare Conference

Company Presentation: Tuesday, September 14 at 5:30 p.m. ET

A live webcast, if recorded, of each presentation can be accessed under “News & Events” in the Investors section of the Company’s website at www.instilbio.com. The archived webcast will be available on the Company’s website shortly after the event.

About Instil Bio

Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.

Contacts:

Brendan Payne

Stern Investor Relations

1-212-362-1200

[email protected]    

Media Contact:

1-833-446-7845 Ext. 1009

[email protected]



Driven Brands to Present at the Goldman Sachs 28th Annual Global Retailing Conference

CHARLOTTE, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) — Driven Brands Holdings Inc. (NASDAQ: DRVN) announces that Jonathan Fitzpatrick, president and chief executive officer, and Tiffany Mason, executive vice president and chief financial officer, will present at the Goldman Sachs 28th Annual Global Retailing Conference on Thursday, September 9, 2021.

The presentation will take place at 4:10 PM ET. It will be webcast and can be accessed by visiting Driven Brands’ Investor Relations website at investors.drivenbrands.com. A replay of the webcast will be available until October 8, 2021.

About Driven Brands

Driven Brands™, headquartered in Charlotte, NC, is the largest automotive services company in North America, providing a range of consumer and commercial automotive needs, including paint, collision, glass, vehicle repair, oil change, maintenance and car wash. Driven Brands is the parent company of some of North America’s leading automotive service businesses including Take 5 Oil Change®, Meineke Car Care Centers®, Maaco®, 1-800-Radiator & A/C®, and CARSTAR®. Driven Brands has more than 4,300 locations across 15 countries, and services over 50 million vehicles annually. Driven Brands’ network generates more than $1 billion in revenue from more than $3 billion in system-wide sales.


Contacts

Shareholder/Analyst inquiries:

Rachel Webb
[email protected]
(704) 644-8125
              Media inquiries:

Media Relations
[email protected]
(704) 644-8129
     



BurgerFi to Participate in the J.P. Morgan Gaming, Lodging, Restaurant & Leisure Management Access Forum

PALM BEACH, Fla., Sept. 02, 2021 (GLOBE NEWSWIRE) — BurgerFi International Inc. (Nasdaq: BFI, BFIIW) (“BurgerFi” or the “Company”), one of the nation’s fastest-growing premium fast-casual concepts, Fast Casuals’ #1 Brand of the Year for 2021 in the Top 100 Movers and Shakers list and the top fast casual better burger chain in USA Today’s 10Best Readers’ Choice award winner for 2021, today announced that management will participate in the J.P. Morgan Gaming, Lodging, Restaurant & Leisure Management Access Forum at the Wynn Las Vegas. Julio Ramirez, Chief Executive Officer, and Mike Rabinovitch, Chief Financial Officer, will host a fireside chat on Monday, September 13, 2021 at 3:45 p.m. Pacific Time (6:45 p.m. Eastern Time). The Company will also host 1×1 investor meetings throughout the day.

The presentation will be webcast live and available for replay for 30 days. The webcast can be accessed directly here, or under the “News & Events” tab of the Company’s Investor Relations website at ir.burgerfi.com.

About BurgerFi International (Nasdaq: BFI, BFIIW)

Established in 2011, BurgerFi is among the nation’s fastest-growing better burger concepts with approximately 120 BurgerFi restaurants domestically and internationally. The concept is chef-founded and is committed to serving fresh food of transparent quality. BurgerFi uses 100% American angus beef with no steroids, antibiotics, growth hormones, chemicals, or additives. BurgerFi’s menu also includes high quality wagyu beef, antibiotic and cage-free chicken offerings, fresh, hand-cut sides and custard shakes and concretes. BurgerFi was named QSR Magazine’s Breakout Brand of 2020, Fast Casual’s 2021 #1 Brand of the Year, was named “Best Burger Joint” by Consumer Reports and fellow public interest organizations in the 2019 Chain Reaction Study, was listed as a “Top Restaurant Brand to Watch” by Nation’s Restaurant News in 2019 and was included in Inc. Magazine’s Fastest Growing Private Companies List. To learn more about BurgerFi or to find a full list of locations, please visit www.burgerfi.com. Download the BurgerFi App on iOS or Android devices for rewards and ‘Like’ BurgerFi on Facebook or follow @BurgerFi on Instagram and Twitter.

BurgerFi® is a Registered Trademark of BurgerFi IP, LLC, a wholly-owned subsidiary of BurgerFi. 

Investor Relations:

ICR

Lynne Collier
[email protected]
646-430-2216

Company Contact:

BurgerFi International Inc.

[email protected]

Media Relations Contact:

Quinn PR

Laura Neroulias
[email protected]



Sigilon Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in two upcoming healthcare investor conferences.

Presentation Details:

Event: Morgan Stanley 19th Annual Global Healthcare Conference
Date:
Friday, September 10, 2021
Time: 8:00 AM ET
Details:
Live Fireside Chat

Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: 7:00 AM ET
Details:
On Demand Corporate Presentation

Webcasts of the Morgan Stanley fireside chat and the H.C. Wainwright corporate presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company’s website at www.sigilon.com. A replay of each webcast will be available at the same location following the event.

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor Contact

Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
[email protected]
617-586-3837

Media Contacts

Amy Bonanno
Solebury Trout
[email protected]
914-450-0349

Brandon Hagen
Manager, Communications
Sigilon Therapeutics
[email protected]
617-586-2851



Alector to Present at Upcoming Virtual Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming virtual investor conferences:

  • Citi’s 16th Annual Biopharma Virtual Conference
    • Wednesday, September 8, 2021 at 11:35 a.m. ET, What’s Next for Neurodegenerative Diseases Panel
    • Thursday, September 9, 2021 at 1:25 p.m. ET, Fireside Chat
  • The 2021 Wells Fargo Virtual Healthcare Conference
    • Friday, September 10, 2021 at 2:00 p.m. ET, Corporate Presentation
  • The Morgan Stanley 19th Annual Global Healthcare Conference
    • Monday, September 13, 2021 at 11:45 a.m. ET, Fireside Chat

Live webcasts of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 30 days following the presentation dates.

About Alector

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies.  Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Alector Contacts

Michelle Corral
VP, Communications and Investor Relations
650-808-7016
[email protected]

1AB (media)
Dan Budwick
973-271-6085
[email protected]

Argot Partners (investors)
Laura Perry/Eric Kasper
Argot Partners
212.600.1902
[email protected]

 



Tuesday Morning Announces Reporting Date for Fourth Quarter and Fiscal 2021 Results

DALLAS, Sept. 02, 2021 (GLOBE NEWSWIRE) — Tuesday Morning (NASDAQ: TUEM), a leading off-price retailer of home goods and décor, today announced that the Company will hold a conference call to discuss its fourth quarter and fiscal 2021 financial results on Thursday, September 9th, 2021 at 8:00 am Central Time. A press release detailing the Company’s financial results will be issued before the market opens and prior to the conference call.

A live webcast of the conference call will be available in the investor relations section of the Company’s website, www.tuesdaymorning.com. Investors and analysts interested in listening to the call are invited to dial 877-407-9716 or 201-493-6779, if calling internationally, approximately ten minutes prior to the start of the call. A replay of the webcast will be posted on the website for 90 days.

About Tuesday Morning

Tuesday Morning Corporation is one of the original off-price retailers specializing in name-brand, high-quality products for the home, including upscale home textiles, home furnishings, housewares, gourmet food, toys and seasonal décor, at prices generally below those found in boutique, specialty and department stores, catalogs and on-line retailers. Based in Dallas, Texas, the Company opened its first store in 1974 and currently operates 490 stores in 40 states. More information and a list of store locations may be found on the Company’s website at www.tuesdaymorning.com

Investors:

Caitlin Churchill, ICR
[email protected]
203-682-8200

Media:

[email protected]



Archrock to Participate in Upcoming Virtual Investor Conferences

HOUSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) — Archrock, Inc. (NYSE:AROC) (“Archrock”) announced today it will participate in meetings with investors at the following conferences on September 8, 2021:

  • Brad Childers, President and Chief Executive Officer, will present at the Barclays CEO Energy-Power Conference at 2:35 p.m. Central Time
  • Doug Aron, Chief Financial Officer, will present at the 10th Annual Gateway Investor Conference at 11:00 a.m. Central Time

The webcast links and slides will be available prior to the commencement of the meetings under the “Investors” tab of our website, www.archrock.com.

About Archrock

Archrock is an energy infrastructure company with a pure-play focus on midstream natural gas compression.  Archrock is the leading provider of natural gas compression services to customers in the oil and natural gas industry throughout the U.S. and a leading supplier of aftermarket services to customers that own compression equipment in the U.S. Archrock is headquartered in Houston, Texas. For more information, please visit www.archrock.com.

SOURCE: Archrock, Inc.


For information, contact:

Megan Repine
Vice President, Investor Relations
(281) 836-8360
[email protected]